An update on the MajesTEC-1 trial: the efficacy of less frequent dosing of teclistamab in RRMM

Download video

An update on the MajesTEC-1 trial: the efficacy of less frequent dosing of teclistamab in RRMM

68 views

VJHemOnc – Video Journal of Hematology & HemOnc

3 months ago

An update on the MajesTEC-1 trial: the efficacy of less frequent dosing of teclistamab in RRMM

0:34

An update on the MajesTEC-1 trial: the efficacy of less frequent dosing of teclistamab in RRMM

by VJHemOnc – Video Journal of Hematology \& HemOnc

$Updated Efficacy\/Safety Results of MajesTEC-1 (Teclistamab) at ASCO 2022$

11:22

Updated Efficacy\/Safety Results of MajesTEC-1 (Teclistamab) at ASCO 2022

by International Myeloma Foundation

$2-year follow-up of MajesTEC-1: teclistamab in R\/R multiple myeloma$

0:46

2-year follow-up of MajesTEC-1: teclistamab in R\/R multiple myeloma

by VJHemOnc – Video Journal of Hematology \& HemOnc

2:43

Updated results from MajesTEC-1

by VJHemOnc – Video Journal of Hematology \& HemOnc

7:25

Updated phase 1 results of teclistamab, a BCMA × CD3 bispecific antibody, in RRMM

by International Myeloma Foundation

7:03

Teclistamab for RRMM: Long term follow up data from MajesTEC-1

by ecancer

$Update on Phase I trial of teclistamab in R\/R myeloma$

3:45

Update on Phase I trial of teclistamab in R\/R myeloma

by VJHemOnc – Video Journal of Hematology \& HemOnc

9:57

Teclistamab, a BCMA × Cd3 Bispecific Antibody, in Pts with RRMM: Updated Phase 1 Results

by International Myeloma Foundation

6:49

An Update on the Use of Bispecific Antibodies in Myeloma | Mohamad Mohty, MD | IMS 2024

by HealthTree Foundation for Multiple Myeloma

5:32

Myeloma Made Simple: Bispecific Antibody Targets Made Simple | Myeloma Targeting with Bispecifics

by International Myeloma Foundation

58:00

Know Your Myeloma Immunotherapy: Teclistamab and other Bispecifics

by HealthTree Foundation for Multiple Myeloma

$Durability of Responses With Biweekly Dosing of Teclistamab in Pts With Relapsed\/Refractory Myeloma$

5:06

Durability of Responses With Biweekly Dosing of Teclistamab in Pts With Relapsed\/Refractory Myeloma

by International Myeloma Foundation

$MajesTEC-2 update: teclistamab plus lenalidomide in R\/R multiple myeloma$

0:45

MajesTEC-2 update: teclistamab plus lenalidomide in R\/R multiple myeloma

by VJHemOnc – Video Journal of Hematology \& HemOnc

$Updated data: Phase 1\/2 MajesTEC-1 study evaluating teclistamab, a BCMA x CD3 bispecific antibody$

7:25

Updated data: Phase 1\/2 MajesTEC-1 study evaluating teclistamab, a BCMA x CD3 bispecific antibody

by ecancer

4:56

Updates on Phase 1b TRIMM-2 Study Results of Teclistamab + Daratumumab Presented at EHA 2022

by International Myeloma Foundation

$MajesTEC-1: update on RP2D of teclistamab in R\/R myeloma$

3:05

MajesTEC-1: update on RP2D of teclistamab in R\/R myeloma

by VJHemOnc – Video Journal of Hematology \& HemOnc

$Updated Results from MajesTEC-1 Study in Relapsed\/Refractory Multiple Myeloma$

8:00

Updated Results from MajesTEC-1 Study in Relapsed\/Refractory Multiple Myeloma

by CheckRare

1:59

A subgroup analysis of MajesTEC-1: teclistamab in multiple myeloma with high-risk features

by VJHemOnc – Video Journal of Hematology \& HemOnc

1:53

MajesTEC‐1 update: rates of infection in patients with myeloma receiving teclistamab

by VJHemOnc – Video Journal of Hematology \& HemOnc

$Real-world study determining the safety and efficacy of teclistamab in R\/R multiple myeloma$

4:13

Real-world study determining the safety and efficacy of teclistamab in R\/R multiple myeloma

by VJHemOnc – Video Journal of Hematology \& HemOnc

9:36

What are the real-world outcomes following treatment with teclistamab in RRMM?

by Multiple Myeloma Hub

$Safety and efficacy of teclistamab in patients with triple-class exposed R\/R myeloma$

1:43

Safety and efficacy of teclistamab in patients with triple-class exposed R\/R myeloma

by VJHemOnc – Video Journal of Hematology \& HemOnc

$Real-world efficacy \& safety of teclistamab in patients with heavily pretreated R\/R multiple myeloma$

6:38

Real-world efficacy \& safety of teclistamab in patients with heavily pretreated R\/R multiple myeloma

by VJHemOnc – Video Journal of Hematology \& HemOnc

Best on Vidoe

An update on the MajesTEC-1 trial: the efficacy of less frequent dosing of teclistamab in RRMM